

## This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
<b>Infectious disease</b>				
Malaria	<i>Plasmodium falciparum</i> dihydroorotate dehydrogenase (PfDHODH)	<i>In vitro</i> and rodent studies identified improved analogs of DHODH inhibitors that could help treat malaria. In mice and rats, optimized triazolopyrimidine-based compounds had higher plasma levels than the parent compound. In mice infected with <i>P. berghei</i> , the analogs lowered parasitic burden better than the parent compound. Next steps include toxicology testing.  <b>SciBX 4(23); doi:10.1038/scibx.2011.660</b> <b>Published online June 9, 2011</b>	Patent application filed; licensed to Medicines for Malaria Venture; available for licensing from Medicines for Malaria Venture	Gujjar, R. <i>et al. J. Med. Chem.</i> ; published online April 25, 2011; doi:10.1021/jm200265b <b>Contact:</b> Pradipsinh K. Rathod, University of Washington, Seattle, Wash. e-mail: <a href="mailto:rathod@chem.washington.edu">rathod@chem.washington.edu</a> <b>Contact:</b> Margaret A. Phillips, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas e-mail: <a href="mailto:margaret.phillips@UTSouthwestern.edu">margaret.phillips@UTSouthwestern.edu</a>